Antibody-based immunotherapy of aciclovir resistant ocular herpes simplex virus infections

作者：Bauer Dirk; Keller Jessica; Alt Mira; Schubert Axel; Aufderhorst Ulrich Wilhelm; Palapys Vivien; Kasper Maren; Heilingloh Christiane Silke; Dittmer Ulf; Laffer Bjoern; Eis Huebinger Anna Maria; Verjans Georges M; Heiligenhaus Arnd; Roggendorf Michael; Krawczyk Adalbert^*

来源：Virology, 2017, 512: 194-200.

DOI：10.1016/j.virol.2017.09.021

• HSV
• Infection of the eye
• Aciclovir resistance
• ARN
• Humanized Anti-HSV-antibody

The increasing incidence of aciclovir-(ACV) resistant strains in patients with ocular herpes simplex virus (HSV) infections is a major health problem in industrialized countries. In the present study, the humanized monoclonal antibody (mAb) hu2c targeting the HSV-1/2 glycoprotein B was examined for its efficacy towards ACV-resistant infections of the eye in the mouse model of acute retinal necrosis (ARN). BALB/c mice were infected by microinjection of an ACV-resistant clinical isolate into the anterior eye chamber to induce ARN and systemically treated with mAb hu2c at 24 h prior (pre-exposure prophylaxis) or at 24, 40, and 56 h after infection (post exposure immunotherapy). Mock treated controls and ACV-treated mice showed pronounced retinal damage. Mice treated with mAb hu2c were almost completely protected from developing ARN. In conclusion, mAb hu2c may become a reliable therapeutic option for drug/ACV-resistant ocular HSV infections in humans in order to prevent blindness.

• 出版日期2017-12